OR Royalties Inc. (NYSE:OR) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of OR Royalties Inc. (NYSE:OR) have received a consensus recommendation of “Moderate Buy” from the ten analysts that are currently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $46.50.

OR has been the topic of a number of research analyst reports. Wall Street Zen cut shares of OR Royalties from a “buy” rating to a “hold” rating in a research note on Saturday, June 6th. TD Securities reissued a “hold” rating on shares of OR Royalties in a research note on Monday, February 23rd. Royal Bank Of Canada reissued an “outperform” rating and issued a $56.00 price target on shares of OR Royalties in a research note on Friday, April 10th. Zacks Research cut shares of OR Royalties from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Finally, Weiss Ratings cut shares of OR Royalties from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 4th.

Institutional Investors Weigh In On OR Royalties

Institutional investors have recently added to or reduced their stakes in the stock. Alps Advisors Inc. acquired a new stake in OR Royalties during the 3rd quarter worth $2,649,000. Navellier & Associates Inc. acquired a new stake in OR Royalties during the 3rd quarter worth $1,451,000. Vanguard Group Inc. boosted its stake in OR Royalties by 2.2% during the 4th quarter. Vanguard Group Inc. now owns 7,847,015 shares of the basic materials company’s stock worth $277,965,000 after purchasing an additional 167,970 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in OR Royalties by 39.2% during the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,543,667 shares of the basic materials company’s stock worth $302,419,000 after purchasing an additional 2,124,421 shares during the last quarter. Finally, Van ECK Associates Corp boosted its stake in OR Royalties by 20.5% during the 3rd quarter. Van ECK Associates Corp now owns 15,561,057 shares of the basic materials company’s stock worth $623,686,000 after purchasing an additional 2,650,333 shares during the last quarter. Institutional investors and hedge funds own 68.52% of the company’s stock.

OR Royalties Price Performance

Shares of NYSE OR opened at $33.83 on Friday. The stock has a market capitalization of $6.34 billion, a price-to-earnings ratio of 25.24 and a beta of 0.70. OR Royalties has a 12 month low of $24.76 and a 12 month high of $48.06. The firm’s 50 day simple moving average is $37.67 and its 200-day simple moving average is $38.71.

OR Royalties (NYSE:OR) last issued its quarterly earnings data on Wednesday, May 6th. The basic materials company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. The business had revenue of $102.83 million for the quarter, compared to analysts’ expectations of $103.27 million. OR Royalties had a net margin of 78.09% and a return on equity of 15.10%. Analysts anticipate that OR Royalties will post 1.4 earnings per share for the current fiscal year.

OR Royalties Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Tuesday, June 30th will be paid a $0.065 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $0.26 dividend on an annualized basis and a yield of 0.8%. This is an increase from OR Royalties’s previous quarterly dividend of $0.06. OR Royalties’s dividend payout ratio is 16.42%.

About OR Royalties

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.